南洋股份(002212.SZ):明泰資本已累計減持3750.51萬股
格隆匯2月2日丨南洋股份(002212.SZ)公佈,截至2020年2月2日,明泰資本以集中競價方式共計減持公司股份1061.225萬股,佔公司總股本的0.92%;以大宗交易方式共計減持公司股份189.28萬股,佔公司總股本的0.16%;以協議轉讓方式減持公司股份2500萬股,佔公司總股本的2.16%;合計減持約3750.51萬股。減持股份來源均為非公開發行股份。截至2020年1月31日,前述減持計劃中以集中競價方式減持股份的實施時間已過半。
此次減持後,明泰資本持有股份1.04億股,佔總股本比例8.98%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.